|
|
|
|
| Stem cells are the backbone of many allogeneic therapies and where they come from affects development and supply chain logistics, particularly cryopreservation. What temperatures are ideal to maintain product potency? How do you build a reliable cold chain? How do you work with existing infrastructure to allow for an “off-the-shelf” therapy? Don’t miss the next Cell & Gene Live digital event! Registration is free thanks to the support of Charter Medical and Bio-Techne. |
|
|
|
|
By Tyler Menichiello, contributing editor | The downstream separation of AAV capsids affects end-product purity and has been identified as a key pain point of the industry. Ultragenyx’s Dennis Huang advises starting with higher-quality yields upstream. |
|
|
|
|
|
|
| Set Your Oversight Early, But Do Not Dictate All The Rules | Q&A | Pharmatech Associates - A USP Company | As more and more sponsors partner with CDMOs to leverage their expertise and capabilities, utilizing the right framework to manage a partner is crucial for the relationship to function optimally. |
|
|
| Lentiviral Vector Platform: Right The First Time | Article | By Mercedes Segura, Dawn Maier, and Bojiao Yin, ElevateBio | Leverage the right LVV manufacturing platform to accelerate timelines, better manage costs, and transform product development and potential for success so therapies can reach patients in need. |
|
|
|
|
|
|
| Connect With Cell & Gene: |
|
|
|
